<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD"><gtr:id>59EE6C94-CB2C-4AB3-9A0B-EAAF5A6550CD</gtr:id><gtr:name>The Pirbright Institute</gtr:name><gtr:address><gtr:line1>Ash Road</gtr:line1><gtr:line2>Pirbright</gtr:line2><gtr:line4>Woking</gtr:line4><gtr:line5>Surrrey</gtr:line5><gtr:postCode>GU24 0NF</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/349B9E60-9920-4232-A023-A9B7CBC6868B"><gtr:id>349B9E60-9920-4232-A023-A9B7CBC6868B</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Paul</gtr:otherNames><gtr:surname>Mertens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FI%2F00001455"><gtr:id>FE273376-A696-444B-AC95-BA395FA13D87</gtr:id><gtr:title>Development of serotype-cross-reactive sub-unit vaccines for African horse sickness and bluetongue viruses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/I/00001455</gtr:grantReference><gtr:abstractText>The project will continue and extend previous studies that involved the development of recombinant Modified Vaccinia Ankara (MVA) strains expressing individual proteins of African horse sickness virus (AHSV), to explore their potential as vaccine components for different AHSV serotypes. These studies have previously shown induction of virus neutralizing antibodies in ponies, following vaccination with MVA expressing AHSV-4 VP2. In particular we are interested in understanding the nature of cross-reactive neutralizing-antibody and protective-immune responses. The project primarily involves working with AHSV proteins expressed in MVA, baculovirus and/or bacterial expression systems as potential vaccine components. Initial vaccination efficacy studies will be carried out in a mouse model system, involving collaboration with Javier Ortego at Valdeolmos in Spain.</gtr:abstractText><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>106544</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>BBSRC has indicated that they do not require a response</gtr:description><gtr:id>751B7CB4-BDBF-4B1A-96B9-40AF0D1139A6</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56e1678c398178.17339129</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>BBSRC has indicated that they do not require a response</gtr:description><gtr:exploitationPathways>BBSRC has indicated that they do not require a response</gtr:exploitationPathways><gtr:id>804FAA3F-D33C-4B27-A86C-5B12752A903A</gtr:id><gtr:outcomeId>56e167dd887c09.54645972</gtr:outcomeId><gtr:sectors><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0C7699DB-FFC3-4010-BFAC-F0631015C3A8</gtr:id><gtr:title>Vaccination of mice with a modified Vaccinia Ankara (MVA) virus expressing the African horse sickness virus (AHSV) capsid protein VP2 induces virus neutralising antibodies that confer protection against AHSV upon passive immunisation.</gtr:title><gtr:parentPublicationTitle>Virus research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856923ad8a88566e9e446dd49d21a909"><gtr:id>856923ad8a88566e9e446dd49d21a909</gtr:id><gtr:otherNames>Calvo-Pinilla E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-1702</gtr:issn><gtr:outcomeId>5a8c5d7f479e28.15019437</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11041467-D399-46AF-AF8E-1BD6AAE00FF9</gtr:id><gtr:title>Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Assay for the Rapid Detection of African Horse Sickness Virus.</gtr:title><gtr:parentPublicationTitle>Transboundary and emerging diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b9de451f30b51ee95c02087f42e2b0ac"><gtr:id>b9de451f30b51ee95c02087f42e2b0ac</gtr:id><gtr:otherNames>Fowler VL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1865-1674</gtr:issn><gtr:outcomeId>57f7bb76715c27.89400764</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0C492CA5-315F-4342-ACC5-0A2821518FF8</gtr:id><gtr:title>Antiserum from mice vaccinated with modified vaccinia Ankara virus expressing African horse sickness virus (AHSV) VP2 provides protection when it is administered 48h before, or 48h after challenge.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/856923ad8a88566e9e446dd49d21a909"><gtr:id>856923ad8a88566e9e446dd49d21a909</gtr:id><gtr:otherNames>Calvo-Pinilla E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>56b89da8898bd0.96956474</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/I/00001455</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>